NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

MAIA Biotechnology, Inc. (MAIA) Stock Analysis

MAIA Biotechnology, Inc. (MAIA) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

MAIA

$1.32

−$0.01 (−0.75%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MAIA with… →

MAIA Key Statistics

As of Sep 4, 2026
Trading
Open
$1.35
Previous Close
$1.33
Day's Range
1.30–1.35
52-Week Range
0.87–3.19
Volume
243.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.26
Valuation
Market Cap
$80.30M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
1.19
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.63
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$22.40M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
60.83M
1-Year Return
−11.41%
Dividend and dates
Avg Volume
516.54K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MAIA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−13.73%
2025−22.73%
2024+69.23%
2023−66.67%
2022 (partial year)−21.30%

As of September 4, 2026.

MAIA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$22.40M—
2024$0.00−$23.25M—
2023$0.00−$19.77M—
2022$0.00−$15.77M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$23.91M−$22.40M—
2024$0.00—−$16.88M−$23.25M—
2023$0.00—−$20.01M−$19.77M—
2022$0.00—−$15.86M−$15.77M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MAIA Valuation vs Biotechnology Median

Median of 656 stocks
MetricMAIABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MAIA Biotechnology, Inc. (MAIA) is capitalised at $80.30M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 13.

MAIA last closed at $1.32 on September 4, 2026. That is −$0.01 (−0.75%) against the previous close. Over the past 52 weeks the price has ranged from $0.87 to $3.19. The latest close sits 51.72% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $22.40M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.63.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 1.19.

Over the trailing twelve months the price has returned −11.41%. Measured over 3 years, that is −10.64% a year compounded. Beta against the wider market is reported at 0.26. Daily returns over the trailing 4 years annualize to a volatility of 89.31%.

Growth & Income

The record shows no dividend for MAIA.

2026 is still running; the price is −13.73% year to date. Across the complete calendar years on file, 2024 returned +69.23% and 2023 returned −66.67%. Of the 3 complete calendar years on file, 1 finished higher.

Peer Comparison

MAIA Biotechnology, Inc. (MAIA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MAIA Biotechnology, Inc. MAIA $80.30M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. MAIA Biotechnology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Visit website →